TOKYO and CAMBRIDGE, Mass., March 3, 2025 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. Weeks after Eisai quietly made its choice, its liquid biopsy partner has revealed Bliss ...

TOKYO and CAMBRIDGE, Mass., Mar 4, 2025 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial ...

The company's U.S. headquarters are in the ON3 complex in Nutley and Clifton. Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records ...

STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi.

Laurel Libby of District 64 in attacking a transgender student. There is no place in Maine for an attack upon a child by an adult. The attack in question is made more heinous because it is ...

courtesy amazon The winners of the 2025 Libby Awards have arrived. PEOPLE can exclusively share the list of the winners for the literary award, which was announced on March 5. Hosted by library ...

Defeat her in next year’s election rather than trying to silence her. Maine Representative Laurel Libby was hardly a household name before this month. But the avowedly conservative Republican ...

Maine State Rep. Laurel Libby has filed a lawsuit against Speaker of the House Ryan Fecteau after she was censured on Feb. 15 for her social media post about a trans high school athlete.

In August, NICE declined to recommend Biogen and Eisai’s Leqembi (lecanemab) for reimbursement. Three months later, NICE followed with the same decision on Lilly’s Kisunla (donanemab).